Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Vaccine development

- PMLiVE

WHO releases new target product profiles for urgently needed antibiotics

The antibiotics are needed to combat key drug-resistant bacteria causing severe bloodstream and urinary tract infections, pneumonia and meningitis

- PMLiVE

MHRA marks 100 years of patient safety through biological standards

The UK regulator highlights its century-long role in establishing safety and consistency benchmarks

- PMLiVE

Lilly and WHO Foundation partner to support global dementia action plan

The partnership will provide financial support and strengthen early detection and intervention efforts

- PMLiVE

University of Liverpool identifies new class of antibiotic in fight against AMR

The new antibiotic class targets two of the WHO’s ‘priority pathogens’

- PMLiVE

UKHSA releases list of pathogens posing ‘greatest risk’ to public health

The agency has listed 24 pathogen families where preparedness efforts are most needed

- PMLiVE

WHO urges US to ‘reconsider’ withdrawal from global health organisation

President Donald Trump said the agency mishandled the COVID-19 pandemic and other global health crises

- PMLiVE

WHO launches $1.5bn emergency appeal to tackle ongoing health crises

The appeal is aimed at providing urgent humanitarian assistance to more than 300 million people

- PMLiVE

WHO announces priority endemic pathogens for urgent vaccine development

The study identifies the 17 pathogens that regularly cause diseases in communities

- PMLiVE

Valneva and LimmaTech Biologics partner to advance Shigella vaccine candidate

There is currently no vaccine approved for Shigella, the second leading cause of fatal diarrhoeal disease globally

- PMLiVE

WHO announces new mRNA vaccine development initiative against human avian influenza

H5N1 was responsible for 889 cases and 463 deaths across 23 countries from 2003 to 2024

- PMLiVE

WHO and CEPI call for broader research strategy to prepare for future pandemics

They have highlighted the importance of expanding research to entire families of pathogens

- PMLiVE

GSK and Flagship Pioneering partner in deal worth up to $7bn to discover medicines and vaccines

The companies aim to develop a portfolio of up to ten candidates

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links